N Engl J Med 2021 Feb 13
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Abstract
Background
Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of sunitinib is unclear.
Methods
In this phase 3 trial, we randomly assigned (in a 1:1:1 ratio) patients with advanced renal cell carcinoma and no previous systemic therapy to receive lenvatinib (20 mg orally once daily) plus pembrolizumab (200 mg intravenously once every 3 weeks), lenvatinib (18 mg orally once daily) plus everolimus (5 mg orally once daily), or sunitinib (50 mg orally once daily, alternating 4 weeks receiving treatment and 2 weeks without treatment). The primary end point was progression-free survival, as assessed by an independent review committee in accordance with Response Evaluation Criteria in Solid Tumors, version 1.1. Overall survival and safety were also evaluated.
Results
A total of 1069 patients were randomly assigned to receive lenvatinib plus pembrolizumab (355 patients), lenvatinib plus everolimus (357), or sunitinib (357). Progression-free survival was longer with lenvatinib plus pembrolizumab than with sunitinib (median, 23.9 vs. 9.2 months; hazard ratio for disease progression or death, 0.39; 95% confidence interval [CI], 0.32 to 0.49; P<0.001) and was longer with lenvatinib plus everolimus than with sunitinib (median, 14.7 vs. 9.2 months; hazard ratio, 0.65; 95% CI, 0.53 to 0.80; P<0.001). Overall survival was longer with lenvatinib plus pembrolizumab than with sunitinib (hazard ratio for death, 0.66; 95% CI, 0.49 to 0.88; P = 0.005) but was not longer with lenvatinib plus everolimus than with sunitinib (hazard ratio, 1.15; 95% CI, 0.88 to 1.50; P = 0.30). Grade 3 or higher adverse events emerged or worsened during treatment in 82.4% of the patients who received lenvatinib plus pembrolizumab, 83.1% of those who received lenvatinib plus everolimus, and 71.8% of those who received sunitinib. Grade 3 or higher adverse events occurring in at least 10% of the patients in any group included hypertension, diarrhea, and elevated lipase levels.
Conclusions
Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib. (Funded by Eisai and Merck Sharp and Dohme; CLEAR ClinicalTrials.gov number, NCT02811861.).
Related Questions
How do you reconcile the lack of OS benefit in the CLEAR trial comparing Lenvatinib + Pembrolizumab to Sunitinib, to the very impressive ORR and mPFS benefit seen?
At the primary analysis point of the phase III open-label, CLEAR study (Study 307/KEYNOTE-581), with a median survival follow-up of 26.6 months, lenvatinib plus pembrolizumab showed superior efficacy versus sunitinib in the first-line treatment of patients with advanced renal cell carcinoma. (Motzer...
Is there a difference in the incidence of serious immune-related adverse events with the lenvatinib + pembrolizumab combination vs pembrolizumab alone in endometrial cancer?
Yes, high risk of both hypertension and diarrhea. The diarrhea can be very difficult to manage. The lenvatinib definitely adds a level of complexity to the management of pembro side effects. This requires dose reductions and interruptions, maybe even hospitalization for dehydration/renal insufficien...
How would you treat a patient with low burden metastatic renal cell carcinoma that progressed on cabozantinib who is not a candidate for immunotherapy?
For patients with low volume mRCC and a slow growth rate, I favor treatment with an oligiometastatic disease paradigm. The definition of oligo- disease is not standardized though a numerical cutoff of 5 or fewer metastasis is widely used. It is important to understand that biology is the most critic...
How would use of adjuvant pembrolizumab after nephrectomy for ccRCC impact your treatment choice for metastatic recurrence?
I think treatment selection after recurrence/metastases will depend on the timing after adjuvant pembrolizumab has been completed. If it's about 9 months or more, I think re-challenge with pure IO/IO combination is fair, especially if a patient tolerated pembrolizumab well. If it's within 3-6 months...
When, if ever, would you consider use of nivo/ipi for favorable risk metastatic ccRCC?
I do think about nivo/ipi for a subset of patients with favorable risk disease -- usually younger patients who are shooting for a complete response. In the favorable risk subset of patients in CheckMate 214, the complete responses are higher than even in the intermediate-poor risk. Patients who have...
What data do you view as most impactful to treatment decisions in 1L metastatic ccRCC?
Certainly overall survival is the ultimate endpoint, but I would not discount PFS and complete responses (CRs do drive survival benefit in a small subset of patients as evidenced by high dose IL-2). Currently we have no data comparing IO/IO vs IO/TKI combinations head to head, so we generally select...
What is your experience with comparative toxicities of the available 1L combination regimens in metastatic ccRCC?
Toxicity profile is very important in choosing a regimen, noting that no direct comparisons exist. Ipi/nivo is characterized by more initial, inflammatory toxicity, but relatively well tolerated nivo monotherapy maintenance and the ability to be off all therapy for a subset of patients. IO/TKI combo...
What is your preferred regimen for metastatic clear cell RCC following progression on IO/TKI?
Patients with progression after IO-based therapies are increasingly common. Standard options include single agent TKI (cabozantinib most commonly used after axi/pembro) and lenvatinib/everolimus. The role of additional IO-based therapy in this setting is unproven, although there are data with lenvat...
What would be the treatment options for metastatic clear cell carcinoma of kidney who develops recurrent thrombosis despite therapeutic anticoagulant on cabozantinib in second line treatment after failing immunotherapy?
Any TKI will potentially increase the risk of thrombosis, so this is a bit of a challenge for the patient. However, cabozantinib, based on personal experience, is more likely to cause this complication and other TKIs may be better in this regard. If you need to completely avoid TKIs, everolimus mono...
When using IO therapy for front line treatment of metastatic RCC, is there a role for cytoreductive nephrectomy?
The role and timing of debulking nephrectomy in mRCC has been evolving over the last several years. This is in part due to CARMENA, which in my opinion reinforced that patient selection is critical, and in part due to increased activity of systemic therapy. I think patients with limited IMDC risk fa...
For metastatic clear cell RCC, would you consider cabozantinib + nivolumab after progression on first line ipilimumab + nivolumab?
The management of metastatic clear cell RCC continues to evolve since the approval of nivolumab for salvage therapy post TKI tx. Given the activity of anti PD1 inhibition in the salvage setting, the field has investigated multiple combinations of such agents in the first line setting. The rationale ...
What is your preferred first-line therapy for patients with newly diagnosed intermediate- or poor-risk metastatic clear cell RCC?
For intermediate and poor risk advanced clear cell renal cell carcinoma, combination therapy is the standard of care with 4 different regimens showing an improvement in overall survival vs sunitinib: nivolumab/ipilimumab, pembrolizumab/axitinib, cabozantinib/nivolumab, and pembrolizumab/lenvatinib. ...